Skip to main content

Intracerebral Haemorrhage

6
Pipeline Programs
8
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
5
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

General Cardiac Technology
1 program
1
Aspirin 75 mg dailyPhase 3
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Aspirin 75 mg dailyPhase 31 trial
Active Trials
NCT07243704Not Yet Recruiting5,676Est. Feb 2029
Renova Therapeutics
Renova TherapeuticsCA - Carlsbad
1 program
1
Aspirin 75 mg dailyPhase 3
Allied Medical
Allied MedicalMO - St. Louis
1 program
1
Aspirin 75 mg dailyPhase 3
Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
Aspirin 75 mg dailyPhase 3
Alliance Pharmaceuticals
1 program
1
IL-1Ra Kineret®Phase 21 trial
Active Trials
NCT03737344Completed25Est. Apr 2021
Eppendorf
EppendorfGermany - Hamburg
1 program
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)N/A1 trial
Active Trials
NCT07553650Not Yet Recruiting12,750Est. Jun 2030
Century Therapeutics
Century TherapeuticsPHILADELPHIA, PA
1 program
Aspirin 75 mg dailyPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Human BioSciencesAspirin 75 mg daily
Alliance PharmaceuticalsIL-1Ra Kineret®
EppendorfMaster Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)

Clinical Trials (3)

Total enrollment: 18,451 patients across 3 trials

NCT07243704Human BioSciencesAspirin 75 mg daily

Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage

Start: Feb 2026Est. completion: Feb 20295,676 patients
Phase 3Not Yet Recruiting
NCT03737344Alliance PharmaceuticalsIL-1Ra Kineret®

BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage

Start: May 2019Est. completion: Apr 202125 patients
Phase 2Completed
NCT07553650EppendorfMaster Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)

Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)

Start: May 2026Est. completion: Jun 203012,750 patients
N/ANot Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.